Evidence map›Paper›PMID 35406744›Full record

ArticleCells2022

The Sin3A/MAD1 Complex, through Its PAH2 Domain, Acts as a Second Repressor of Retinoic Acid Receptor Beta Expression in Breast Cancer Cells.

Nisha Rani Dahiya, Boris A Leibovitch, Rama Kadamb, Nidhi Bansal, Samuel Waxman

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Nisha Rani DahiyaThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Boris A LeibovitchDepartment of Pathology, New York University School of Medicine, New York, NY 10029, USA.ORCID 0000-0001-6771-5906
Rama KadambDepartment of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.ORCID 0000-0002-0157-2305
Nidhi BansalThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0001-6502-3930
Samuel WaxmanThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Tisch Hospital · USAlbert Einstein College of Medicine · USNew York University · US

Funding

Targeted epigenetic therapy of triple-negative breast cancerR01CA158121 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WAXMAN, SAMUEL · 2011 to 2015
$1.6M
NCI NIH HHS R01 CA158121
6 · The paper itself

Abstract

Retinoids are essential in balancing proliferation, differentiation and apoptosis, and they exert their effects through retinoic acid receptors (RARs) and retinoid X receptors (RXRs). RARβ is a tumor-suppressor gene silenced by epigenetic mechanisms such as DNA methylation in breast, cervical and non-small cell lung cancers. An increased expression of RARβ has been associated with improved breast cancer-specific survival. The PAH2 domain of the scaffold protein SIN3A interacts with the specific

Indexed as

Breast NeoplasmsCell Cycle ProteinsReceptors, Retinoic AcidSin3 Histone Deacetylase and Corepressor ComplexChromatinFemaleHumansRepressor ProteinsCell Cycle ProteinsChromatinMAD1L1 protein, humanReceptors, Retinoic AcidRepressor Proteinsretinoic acid receptor betaSIN3A transcription factorSin3 Histone Deacetylase and Corepressor Complexbreast cancerco-immunoprecipitationE-boxHDAC: histone deacetylasesMAD1: MAX dimerization proteinNCoR: nuclear receptor corepressor 1PAH: paired amphipathic domainsRARE: retinoic acid response elementRARβ: retinoic acid receptor betaSin3A

Identifiers

PMID35406744
PMCPMC8997856
OpenAlexW4221105807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.